Get the Stockscreener App
0.00
100.00%
-59.98
After Hours:
60.01
60.01
+
Longboard Pharmaceuticals Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The company is working to improve a portfolio of centrally acting product candidates designed to be selective for specific G protein-coupled receptors (GPCRs). The company is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies.
See More
Previous Close:
$59.98
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$2.34B
Revenue:
-
Net Income/Loss:
$-76.34M
P/E Ratio:
0.00
EPS:
-2.5513
Net Cash Flow:
$-65.93M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$60.03
Longboard Pharmaceuticals Inc Stock (LBPH) Company Profile
Name
Longboard Pharmaceuticals Inc
Sector
Industry
Phone
619-592-9775
Address
4275 EXECUTIVE SQUARE, LA JOLLA
Compare LBPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LBPH
Longboard Pharmaceuticals Inc
|
0.00 | 2.34B | 0 | -76.34M | -65.93M | -2.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
405.27 | 104.37B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.13 | 78.59B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
628.32 | 37.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.26 | 31.25B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.51 | 27.21B | 3.30B | -501.07M | 1.03B | -2.1146 |
Longboard Pharmaceuticals Inc Stock (LBPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-10-24 | Initiated | Truist | Buy |
| Jul-01-24 | Reiterated | Cantor Fitzgerald | Overweight |
| May-01-24 | Initiated | Robert W. Baird | Outperform |
| Feb-16-24 | Initiated | Citigroup | Buy |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-27-23 | Initiated | B. Riley Securities | Buy |
| Apr-07-21 | Initiated | Evercore ISI | Outperform |
| Apr-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-21 | Initiated | Citigroup | Buy |
| Apr-06-21 | Initiated | Guggenheim | Buy |
View All
Longboard Pharmaceuticals Inc Stock (LBPH) Latest News
Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) Shares Acquired by State Street Corp - Defense World
Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
Longboard Pharmaceuticals' SWOT analysis: bexicaserin potential drives stock outlook - Investing.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.84 Million Stake in Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) - Defense World
Lundbeck to Buy Longboard Pharma in $2.6 Billion Deal - MSN
Longboard Pharmaceuticals' SWOT analysis: bexicaserin stock poised for growth - Investing.com
Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) Shares Sold by Quantbot Technologies LP - MarketBeat
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Longboard Pharmaceuticals, Inc.LBPH - The Eastern Progress Online
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INSI, LBPH, NBR on Behalf of Shareholders - The Eastern Progress Online
Readystate Asset Management LP Makes New Investment in Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) - MarketBeat
Lundbeck to present data at epilepsy congress - Marketscreener.com
Parkman Healthcare Partners LLC Sells 202,906 Shares of Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) - MarketBeat
Fmr LLC Has $144.99 Million Stock Position in Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) - MarketBeat
Lundbeck acquires all outstanding shares of Longboard Pharma - MSN
Longboard Pharmaceuticals concludes merger with H. Lundbeck A/S By Investing.com - Investing.com Australia
Longboard Pharmaceuticals concludes merger with H. Lundbeck A/S - Investing.com
Lundbeck completes billion dollar acquisition of Longboard Pharmaceuticals - Marketscreener.com
Victory Capital Management Inc. Invests $526,000 in Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) - MarketBeat
Langkawi Corporation completed the acquisition of Longboard Pharmaceuticals, Inc.. - Marketscreener.com
Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) Shares Purchased by Ally Bridge Group NY LLC - MarketBeat
Lundbeck's acquisition conditions for Longboard have been met, closing the deal on December 2 - Marketscreener.com
Longboard Pharmaceuticals stock soars to all-time high of $59.96 By Investing.com - Investing.com Nigeria
Longboard Pharmaceuticals stock soars to all-time high of $59.96 - Investing.com
Bright Minds Buosciences Surges 5,900% Last Week. Attention Turning To Cybin ($CYBN) Rallying 23% On Upcoming... - Daily Scanner
Bright Minds initiated at outperform by Baird, Longboard takeover cited (NASDAQ:DRUG) - Seeking Alpha
KBC Group NV Acquires New Position in Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) - Defense World
Jennison Associates LLC Sells 34,440 Shares of Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) - MarketBeat
Brokerages Set Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) Price Target at $59.56 - MarketBeat
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of MARX, BRKH, MNTX and LPBH - GlobeNewswire Inc.
Longboard Pharmaceuticals Boasts High-Value Epilepsy Assets, Analyst Initiates Coverage - MSN
299,156 Shares in Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) Bought by Braun Stacey Associates Inc. - MarketBeat
Longboard Pharmaceuticals Initiates Phase 3 DEEp Ocean Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies - Marketscreener.com
LBPHLongboard Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs) - Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates B, LBPH, ZUO on Behalf of Shareholders - PR Newswire
Longboard Pharmaceuticals Advances Neurological Treatments - TipRanks
Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - BioSpace
Longboard Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
FMR LLC Reduces Stake in Longboard Pharmaceuticals Inc - GuruFocus.com
How the (LBPH) price action is used to our Advantage - Stock Traders Daily
Vanguard Group Inc's Strategic Acquisition in Longboard Pharmace - GuruFocus.com
Longboard Pharmaceuticals granted Orphan Drug Designation for bexicaserin - TipRanks
Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) Position Increased by Emerald Advisers LLC - MarketBeat
Longboard Pharmaceuticals (NASDAQ:LBPH) Hits New 1-Year High – Here’s What Happened - Defense World
Longboard Pharmaceuticals stock soars to all-time high of $59.95 By Investing.com - Investing.com South Africa
Longboard Pharmaceuticals (NASDAQ:LBPH) Reaches New 52-Week HighShould You Buy? - MarketBeat
500: Something went wrong - Investing.com
Longboard Pharmaceuticals Inc options imply 0.8% move in share price post-earnings - TipRanks
LONGBOARD PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Longboard Pharmaceuticals, Inc.LBPH - Business Wire
Longboard Pharmaceuticals Inc Stock (LBPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):